Omega Ophthalmics was founded in 2011 with the intent to bring a new, first in class intraocular lens to market. The lens represents a real departure from the standard design, though it can still be inserted using a standard technique and incision size. The lens provides a platform for new intraocular innovation, as it creates a protected environment within the capsular bag to house additional refractive implants or time released drugs. There are currently 9 patents both in the US and internationally with more applications pending. The company is privately funded with first-in-man trial and a goal to begin the FDA and/or CE mark approval process.